Heart Tests Were ‘Normal.’ So, Why Did Heart Attack Still Happen?

Your cardiologist said your stress test was normal. 

Your calcium score was zero. 

Your echo looked fine. 

And you still had a heart attack. 

Here's why.

This is not rare.
This is not bad luck.
This is a diagnostic blind spot.

THE REALITY MOST PATIENTS ARE NEVER TOLD

I’m a cardiologist. I trained in standard cardiology. I follow the guidelines.

And I can tell you this:

Most tests we rely on today, stress test, echocardiogram, and coronary calcium scoring, were designed to detect disease after it becomes dangerous.
Not before.

That distinction is exactly why I built Pulse Perfect.

THE “REASSURING” TEST THAT MISSES THE MOST DANGEROUS PLAQUE

The coronary calcium score (CAC) is one of the most commonly used screening tools today.

And when it comes back to zero, patients are told they’re “safe.”

But here’s the truth:

A CAC score of zero does not mean you have no plaque.
It only means you don’t have calcified plaque.

It completely misses soft (non-calcified) plaque, the kind most likely to rupture.

And when soft plaque ruptures, it doesn’t gradually block an artery.

It causes a sudden clot  => to complete blockage  =>heart attack.

Zero calcium ≠ zero risk.
Soft plaque is invisible. And it kills


📚 EVIDENCE BASE

Ahmadi et al., JACC 2016: Non-calcified plaque burden is independently associated with obstructive CAD and MACE, independent of CAC score. Patients with CAC=0 and elevated non-calcified plaque burden remain at elevated risk. Blaha et al., JACC 2011, confirmed that while CAC=0 confers low short-term risk, it does not eliminate risk in high-risk phenotypes.

The stress test Problem no one talks about

A standard treadmill or nuclear stress test detects ischemia, reduced blood flow to the heart during exertion. To produce a positive result, a coronary stenosis must be severe enough and cover enough territory to cause detectable wall motion abnormalities or EKG changes.

The problem is that a 40–60% stenosis, especially in a single vessel, may not produce ischemia detectable by stress testing. Plaque builds, stenosis progresses, and stress tests keep coming back normal.

I have had patients with five consecutive normal stress tests. Their most recent was six months before they came to me. On CCTA, they had multi-vessel disease.

A normal stress test means your heart is coping.
It does NOT mean your arteries are clean.

OUR “NORMAL” CHOLESTEROL MAY NOT BE NORMAL

I want to talk about LDL for a moment. Your doctor told you your LDL. If it was under 130, maybe under 100, you were probably reassured. LDL-cholesterol has been the cornerstone of cardiovascular risk assessment for 40 years.

LDL-C measures the total amount of cholesterol inside LDL particles.
What actually causes plaque is the particles themselves, specifically, the ApoB protein that coats the surface of every atherogenic particle.
One ApoB = one atherogenic particle. 

One particle = one plaque-forming event.


LDL-C measures cholesterol content.
ApoB measures the number of plaque-causing particles.

In my four published cases, every patient had an acceptable standard LDL-C. Each had elevated ApoB and/or elevated LDL particle number.
In one case, LDL particle count reached 1,900 nmol/L, nearly double the high-risk threshold, despite a standard LDL of 117 mg/dL.

We also routinely test Lp(a).
Lp(a) is an independent, genetically-determined cardiovascular risk factor elevated in approximately 20% of the population. It is not captured on any standard lipid panel.
It is not meaningfully reduced by statins.
Most patients and many physicians have never heard of it.


<p style="font-size: 12px; color: black;">
  📚 EVIDENCE BASE

Sniderman et al., JAMA Internal Medicine 2019: ApoB is a superior predictor of cardiovascular risk as compared to LDL-C across risk strata. Emerging Risk Factors Collaboration (Lancet, 2009): Lp(a) concentration is continuously associated with CAD and stroke risk, independent of other risk factors. Approximately 1 in 5 people carry elevated Lp(a).


</p>
<p style="font-size: 12px; color: black;">
  📚 EVIDENCE BASE

Sniderman et al., JAMA Internal Medicine 2019: ApoB is a superior predictor of cardiovascular risk as compared to LDL-C across risk strata. Emerging Risk Factors Collaboration (Lancet, 2009): Lp(a) concentration is continuously associated with CAD and stroke risk, independent of other risk factors. Approximately 1 in 5 people carry elevated Lp(a).


</p>
<p style="font-size: 12px; color: black;">
  📚 EVIDENCE BASE

Sniderman et al., JAMA Internal Medicine 2019: ApoB is a superior predictor of cardiovascular risk as compared to LDL-C across risk strata. Emerging Risk Factors Collaboration (Lancet, 2009): Lp(a) concentration is continuously associated with CAD and stroke risk, independent of other risk factors. Approximately 1 in 5 people carry elevated Lp(a).


</p>
<p style="font-size: 12px; color: black;">
  📚 EVIDENCE BASE

Sniderman et al., JAMA Internal Medicine 2019: ApoB is a superior predictor of cardiovascular risk as compared to LDL-C across risk strata. Emerging Risk Factors Collaboration (Lancet, 2009): Lp(a) concentration is continuously associated with CAD and stroke risk, independent of other risk factors. Approximately 1 in 5 people carry elevated Lp(a).


</p>
<p style="font-size: 12px; color: black;">
  📚 EVIDENCE BASE

Sniderman et al., JAMA Internal Medicine 2019: ApoB is a superior predictor of cardiovascular risk as compared to LDL-C across risk strata. Emerging Risk Factors Collaboration (Lancet, 2009): Lp(a) concentration is continuously associated with CAD and stroke risk, independent of other risk factors. Approximately 1 in 5 people carry elevated Lp(a).


</p>

📚 EVIDENCE BASE

Sniderman et al., JAMA Internal Medicine 2019: ApoB is a superior predictor of cardiovascular risk as compared to LDL-C across risk strata. Emerging Risk Factors Collaboration (Lancet, 2009): Lp(a) concentration is continuously associated with CAD and stroke risk, independent of other risk factors. Approximately 1 in 5 people carry elevated Lp(a).


A Real Case:

What I found in a 48-year-old pharmacist with a CAC score of zero

He came to me four months after his PCP ran a calcium score. 

The score was zero, and he was told it was reassuring. He had no symptoms. 

His stress test at his cardiologist's office was normal. 

His echocardiogram was normal.

He was a pharmacist. He dispensed cardiac medications every day. He thought he understood the system.

We ran a Coronary CT Angiography with Cleerly AI plaque analysis, the same technology used in the landmark ISCHEMIA trial imaging sites. The findings: 70% stenosis in the proximal left anterior descending artery, caused entirely by non-calcified plaque. The total non-calcified plaque volume in that vessel alone was 807 cubic millimeters.

We added HeartFlow FFRCT, a computational fluid dynamics analysis that determines whether a stenosis is actually restricting blood flow to the heart. His FFR value was 0.79 in the mid-LAD. Anything below 0.80 is hemodynamically significant.

He underwent cardiac catheterization and coronary stenting.

Without advanced imaging, this would have been
heart attack waiting to happen.

📚 EVIDENCE BASE

SYNTAX trial, NEJM 2009, and ISCHEMIA trial, NEJM 2020: Established the role of CCTA and FFRCT in guiding revascularization decisions. The NXT trial (Norgaard et al., JACC 2014) demonstrated FFRCT's 86% diagnostic accuracy vs. invasive FFR for hemodynamic significance, now a Class IIa recommendation in ESC guidelines.

What a complete cardiovascular evaluation at Pulse Perfect looks like 

A comprehensive cardiovascular evaluation includes:

  • Coronary CTA with Cleerly AI Plaque Analysis
    It helps quantify calcified, non-calcified, and low-density (vulnerable) plaque in each vessel.

  • HeartFlow FFRCT when stenosis warrants physiologic assessment
    It guides treatment decisions without invasive catheterization.

  • Advanced lipid panel:
    This includes: ApoB, Lp(a), NMR LipoProfile (LDL-P, small LDL-P, LDL pattern, LP-IR insulin resistance score), and hs-CRP.

  • VO₂ max with full ventilatory threshold analysis
    It is the most powerful predictor of cardiovascular survival available to clinicians.

  • DEXA body composition with visceral adipose tissue quantification.

  • TruAge epigenetic testing
    It helps determine the biological age, organ-system ages, and pace of aging.


Every patient receives a tailored 360° cardiovascular blueprint, not just numbers but a plan targeting specific treatment. It includes an action plan, training zone prescriptions, a nutrition framework, and a supplement protocol.

This is not concierge medicine. This is what cardiovascular medicine should have always been.

I did not leave standard cardiology because it failed my patients. I left because I saw how much more was possible, and I could not unsee it.


If you’ve been told:

  • “Your stress test is normal.”

  • “Your calcium score is zero.”

  • “Your echo looks fine.”

…and something still feels off—

You’re not overthinking it.
You’re asking the right question.

If you want the full picture, not partial reassurance, come see us at
Pulse Perfect  · Piscataway, NJ  ·  908-201-3402  ·  


#preventivecardiology #hearthealth #coronarycta #FFRCT #ApoB #Lpa #cardiovascularprevention #pulseperfect #longevitymedicine #precisionmedicine

 

 


Pulse Perfect

Pulse Perfect

PulsePerfect @ 2025. All rights reserved.

216 Selton Road, Suite E3

Piscataway, NJ 08854

908-201-3402

Pulse Perfect

Pulse Perfect

PulsePerfect @ 2025. All rights reserved.

216 Selton Road, Suite E3

Piscataway, NJ 08854

908-201-3402

Pulse Perfect

Pulse Perfect

PulsePerfect @ 2025. All rights reserved.

216 Selton Road, Suite E3

Piscataway, NJ 08854

908-201-3402

Pulse Perfect

Pulse Perfect

PulsePerfect @ 2025. All rights reserved.

216 Selton Road, Suite E3

Piscataway, NJ 08854

908-201-3402